| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/25/2010 | US20100048581 Thiazolyl compounds useful as kinase inhibitors |
| 02/25/2010 | US20100048580 Histamine h3 receptor agents, preparation and therapeutic uses |
| 02/25/2010 | US20100048579 Pyridazine-, pyridine- and pyrane-derivatives as gpbar1 agonists |
| 02/25/2010 | US20100048578 Hydrazide compound and harmful arthropod-controlling agent containing the same |
| 02/25/2010 | US20100048577 Method for treating benign prostate hyperplasia using resveratrol |
| 02/25/2010 | US20100048576 PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS |
| 02/25/2010 | US20100048575 Novel tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications |
| 02/25/2010 | US20100048574 NOVEL HETEROCYCLIC NF-kB INHIBITORS |
| 02/25/2010 | US20100048573 Methods of Inhibiting Bacterial Virulence and Compounds Relating Thereto |
| 02/25/2010 | US20100048572 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| 02/25/2010 | US20100048571 Organic Compounds |
| 02/25/2010 | US20100048570 Thiazolidine derivatives and methods for the preparation thereof |
| 02/25/2010 | US20100048569 Diazole derivatives |
| 02/25/2010 | US20100048568 Pyrimidine hydrazide compounds as pgds inhibitors |
| 02/25/2010 | US20100048567 Inhibitors of syk and JAK protein kinases |
| 02/25/2010 | US20100048566 Antibacterial quinoline derivatives |
| 02/25/2010 | US20100048565 Benzimidazole derivatives |
| 02/25/2010 | US20100048564 Fused bicyclic heteroaryl derivative |
| 02/25/2010 | US20100048563 Substituted indolepyridinium as anti-infective compounds |
| 02/25/2010 | US20100048562 Organic compounds |
| 02/25/2010 | US20100048561 Quinazolines for pdk1 inhibition |
| 02/25/2010 | US20100048560 Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| 02/25/2010 | US20100048559 PYRIDO(3,2-d)PYRIDMIDINES USEFUL FOR TREATING VIRAL INFECTIONS |
| 02/25/2010 | US20100048558 Thienopyridines |
| 02/25/2010 | US20100048557 Triazolopyridine JAK Inhibitor Compounds and Methods |
| 02/25/2010 | US20100048556 Quinoxaline derivatives |
| 02/25/2010 | US20100048555 Imidazothiazole derivatives as mark inhibitors |
| 02/25/2010 | US20100048554 Spirocyclic Cyclohexane Compounds |
| 02/25/2010 | US20100048553 Spirocyclic Cyclohexane Compounds |
| 02/25/2010 | US20100048552 such as N-ethyl-3-(9-ethyl-8-oxo-8,9-dihydro-3H-3,4,9-triaza-cyclopenta[a]naphthalen-7-yl)-5-methoxy-benzamide, used to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity |
| 02/25/2010 | US20100048551 Tricyclic Compounds Useful as Inhibitors of Kinases |
| 02/25/2010 | US20100048550 Selective tr-beta 1 agonist |
| 02/25/2010 | US20100048549 Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 |
| 02/25/2010 | US20100048548 Imino-oxazolidines and use thereof |
| 02/25/2010 | US20100048547 Pi 3-kinase inhibitors and methods of their use |
| 02/25/2010 | US20100048545 Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity |
| 02/25/2010 | US20100048544 Pyrrolo (3, 2, 1-ij) quinoline-4-one-derivatives for treating tuberculosis |
| 02/25/2010 | US20100048543 Pyrimidine compounds having ties (tek) inhibitory activity |
| 02/25/2010 | US20100048542 Methods and compositions for treating primary and secondary tumors of the central nervous system (cns) |
| 02/25/2010 | US20100048541 Substituted lactams as inhibitors of abeta protein production |
| 02/25/2010 | US20100048540 Heterocyclic N-Oxides as Hypoxic Selective Protein Kinase Inhibitors |
| 02/25/2010 | US20100048539 Compounds and compositions as protein kinase inhibitors |
| 02/25/2010 | US20100048538 Therapeutical Uses of Eslicarbazepine |
| 02/25/2010 | US20100048537 Heteroaryl derivatives |
| 02/25/2010 | US20100048536 Novel Substituted Diaryl Azepine Derivatives as Integrin Ligands |
| 02/25/2010 | US20100048535 Method and dosage regimens for eliminating a chemical substance in blood |
| 02/25/2010 | US20100048534 Crystalline lestaurtinib hydrates and crystalline lestaurtinib hemihydrate hemiacetonitrileate and crystalline lestaurtinib hemihydrate hemitetrahydrofuranate |
| 02/25/2010 | US20100048533 Lestaurtinib crystalline form 1, crystalline lestaurimib anhydrate and amorphous lestaurimib |
| 02/25/2010 | US20100048532 Benzimidazole Derivatives as Selective Acid Pump Inhibitors |
| 02/25/2010 | US20100048531 GlyT1 RECEPTOR ANTAGONISTS |
| 02/25/2010 | US20100048530 New 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions |
| 02/25/2010 | US20100048529 New 2-Azetidinone Derivatives Useful In The Treatment Of Hyperlipidaemic Conditions |
| 02/25/2010 | US20100048528 Heterocyclic compounds as inhibitors of beta-lactamases |
| 02/25/2010 | US20100048527 Methods and compositions for the non-surgical removal of fat |
| 02/25/2010 | US20100048526 Pharmaceutical composition for transdermal or transmucous administration |
| 02/25/2010 | US20100048525 Androgen treatment in females |
| 02/25/2010 | US20100048524 Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| 02/25/2010 | US20100048523 Compounds, Compositions and Methods for Treating Hormone-Dependent Maladies |
| 02/25/2010 | US20100048522 Ear infections, optionally with antiinflammatory agent |
| 02/25/2010 | US20100048521 Combination of a gluco-korticoid and beta-cyclodextrin conjugated vitamin a-derivate complex |
| 02/25/2010 | US20100048520 Rifaximin anti-rectal dysfunction preparation |
| 02/25/2010 | US20100048519 Methods of treatment for ulcerative colitis using aminosalicylate |
| 02/25/2010 | US20100048518 Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent |
| 02/25/2010 | US20100048517 4-(2-methyl-cyclopentyloxy)-2-trifluoromethyl-benzonitrile; selective androgen receptor modulators; decrease excess sebum secretions; stimulants of hair growth at higher rates of cosmetically acceptable hair growth in patients with alopecia; acne; skin disorders; prostate cancer |
| 02/25/2010 | US20100048515 Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders |
| 02/25/2010 | US20100048514 Use of phospholipids for wound healing |
| 02/25/2010 | US20100048513 Novel inhibitors of chymase |
| 02/25/2010 | US20100048512 Radiation protection drug containing tocopherol or tocotrienol compound ester derivative as active ingredient |
| 02/25/2010 | US20100048511 Complex formulation for preventing or treating osteoporosis which comprises solid dispersion of vitamin d or its derivative and bisphosphonate |
| 02/25/2010 | US20100048510 Dissolution of amyloid fibrils by flavonoids and other compounds |
| 02/25/2010 | US20100048509 Pharmaceutical Composition Comprising Perindopril |
| 02/25/2010 | US20100048508 Mixture and method for reducing cholesterol using hydrophobic microparticles |
| 02/25/2010 | US20100048507 Food/beverage and pharmaceutical composition for oral administration for improvement in acidic urine each comprising fucoidan as active ingredient |
| 02/25/2010 | US20100048506 Composition for treating arthritic disorder |
| 02/25/2010 | US20100048505 Composition Having Effect of Treating, Preventing, or Improving Diabetes or Diabetic Complication and Drink Comprising the Same |
| 02/25/2010 | US20100048504 Crystalline and amorphous forms of beta-l-deoxythymidine |
| 02/25/2010 | US20100048503 Composition for treatment of pancreatic cancer |
| 02/25/2010 | US20100048502 Bhq-caged nucleotide probes photolysable by two-photon excitation |
| 02/25/2010 | US20100048501 Phosphorylated A2A Receptor Agonists |
| 02/25/2010 | US20100048500 Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections |
| 02/25/2010 | US20100048499 Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| 02/25/2010 | US20100048498 Stable non-dihydrate azithromycin oral suspensions |
| 02/25/2010 | US20100048497 Insecticidal active ingredient combinations (formononetins + insecticides) |
| 02/25/2010 | US20100048496 Core 2 GlcNAc-T inhibitors |
| 02/25/2010 | US20100048495 Core 2 GlcNAc-T inhibitors III |
| 02/25/2010 | US20100048494 Natural Products from Vinca |
| 02/25/2010 | US20100048493 Method of administering oral flora-improving agent, antibacterial agent and growth promoter |
| 02/25/2010 | US20100048492 Composition for the prevention and/or treatment of diseases associated with tnf and/or il-12 overexpression |
| 02/25/2010 | US20100048491 Drugs, foods or drinks with the use of algae-derived physiologically active substances |
| 02/25/2010 | US20100048479 Adrenal grk2 activity as a therapeutic target for heart failure |
| 02/25/2010 | US20100048467 Cystine-Knot Fold Cytokine |
| 02/25/2010 | US20100048453 Oxazole and thiazole ppar modulator |
| 02/25/2010 | US20100048451 Novel spill-resistant formulations comprising hydrocolloidal polymers |
| 02/25/2010 | US20100048450 Sumoylation Control Agent and Uses Thereof |
| 02/25/2010 | US20100047910 Supramolecular complexes as photoactivated dna cleavage agents |
| 02/25/2010 | US20100047809 Pca3, pca3 genes, and methods of use |
| 02/25/2010 | US20100047374 Composition for protecting muscle damage |
| 02/25/2010 | US20100047372 Antioxidant and physical performance effects of a grape extract |
| 02/25/2010 | US20100047368 Compositions and methods for the treatment or prevention of chemoresistant neoplasia |
| 02/25/2010 | US20100047367 Compounds and methods for their use |